이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

WuXi Biologics (Cayman) 관리

관리 기준 확인 1/4

WuXi Biologics (Cayman)'s CEO는 Chris Chen, Jan2016 에 임명되었습니다 의 임기는 8.42 년입니다. 총 연간 보상은 CN¥ 96.91M, 4.1% 로 구성됩니다. 4.1% 급여 및 95.9% 보너스(회사 주식 및 옵션 포함). 는 HK$ 167.89M 가치에 해당하는 회사 주식의 0.34% 직접 소유합니다. 167.89M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 6.8 년입니다.

주요 정보

Chris Chen

최고 경영자

CN¥96.9m

총 보상

CEO 급여 비율	4.1%
CEO 임기	8.5yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	6.8yrs

최근 관리 업데이트

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12

Recent updates

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Jun 11

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Jun 11

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Apr 15

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Mar 04

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Dec 08

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

Aug 26

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Aug 10

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Jun 19

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

May 12

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Mar 25

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Mar 13

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

Feb 13

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Jan 30

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Dec 09

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

Nov 20

With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Nov 08

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

Oct 27

WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Sep 08

Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

Aug 15

We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease

Aug 02

Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Jun 29

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

May 16

Here's Why I Think WuXi Biologics (Cayman) (HKG:2269) Might Deserve Your Attention Today

May 03

CEO 보상 분석

Chris Chen 의 보수는 WuXi Biologics (Cayman) 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	CN¥97m	CN¥4m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

보상 대 시장: Chris 의 총 보상 ($USD 13.35M )은 Hong Kong 시장( $USD 886.33K ).

보상과 수익: Chris 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.

CEO

Chris Chen (51 yo)

8.5yrs

테뉴어

CN¥96,911,000

보상

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

리더십 팀

이름	위치	테뉴어	보상	소유권
Ge Li	Founder & Chairman	10.4yrs	데이터 없음	데이터 없음
Zhisheng Chen	CEO & Executive Director	8.5yrs	CN¥96.91m	0.34% CN¥ 164.4m
Weichang Zhou	Honorary President of Global Biologics Development	9.3yrs	CN¥32.89m	0.012% CN¥ 5.6m
Ming Tu	CFO & Executive VP	2.7yrs	데이터 없음	데이터 없음
Lihua Yu	COO & Senior VP	less than a year	데이터 없음	데이터 없음
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	데이터 없음	데이터 없음
Jijie Gu	Chief Scientific Officer & President of Global Biologics Research	no data	데이터 없음	데이터 없음
Lina Fan	Senior VP & Head of Investor Relations	less than a year	데이터 없음	데이터 없음
Cong Ding	VP & Head of Legal Department	no data	데이터 없음	데이터 없음
He Wang	Chief Compliance Officer	1.8yrs	데이터 없음	데이터 없음
Li Xiong	VP & Head of Global Human Resources	no data	데이터 없음	데이터 없음
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 2269 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ge Li	Founder & Chairman	10.4yrs	데이터 없음	데이터 없음
Zhisheng Chen	CEO & Executive Director	10.4yrs	CN¥96.91m	0.34% CN¥ 164.4m
Weichang Zhou	Honorary President of Global Biologics Development	8.2yrs	CN¥32.89m	0.012% CN¥ 5.6m
Jackson Tai	Independent Non-Executive Director	1.2yrs	CN¥710.00k	0.00062% CN¥ 297.0k
James Larrick	Member of Scientific Advisory Board	6.5yrs	데이터 없음	데이터 없음
David D. Ho	Member of Scientific Advisory Board	6.5yrs	데이터 없음	데이터 없음
Wei-Shou Hu	Member of Scientific Advisory Board	6.5yrs	데이터 없음	데이터 없음
Ram Sasisekharan	Member of Scientific Advisory Board	6.5yrs	데이터 없음	데이터 없음
William Robert Keller	Independent Non-Executive Director	7.2yrs	CN¥906.00k	0.00053% CN¥ 253.9k
Yanling Cao	Non-Executive Director	8.2yrs	데이터 없음	데이터 없음
Yibing Wu	Non-Executive Director	8.2yrs	데이터 없음	데이터 없음
Kenneth Walton Hitchner	Independent Non-Executive Director	4.1yrs	CN¥933.00k	0.0049% CN¥ 2.3m

6.8yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 이사회: 2269 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

WuXi Biologics (Cayman) 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

CEO & Executive Director recently sold HK$6.6m worth of stock

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Independent Non-Executive Director recently bought HK$3.0m worth of stock

Recent updates

CEO & Executive Director recently sold HK$6.6m worth of stock

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Less than half of directors are independent

Consensus EPS estimates fall by 18%

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

Investor sentiment deteriorates as stock falls 16%

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 21%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Consensus revenue estimates fall by 14%

Investor sentiment deteriorates as stock falls 28%

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 20% undervalued

Board Member recently sold HK$25m worth of stock

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS misses analyst expectations

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Investor sentiment improved over the past week

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching